Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.

Bonomo, Lauren; Levitt, Jacob O

Bonomo, Lauren; Levitt, Jacob O.

Affiliation

Bonomo L; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Levitt JO; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Cutis ; 101(5): 367-369, 2018 May.

Article in En | MEDLINE | ID: mdl-29894526

Subject(s)

Antibodies, Monoclonal/therapeutic use; Pityriasis Rubra Pilaris/drug therapy; Aged; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal, Humanized; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Pityriasis Rubra Pilaris/pathology; Severity of Illness Index

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pityriasis Rubra Pilaris / Antibodies, Monoclonal Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Cutis Year: 2018 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links